Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

Sodium oxybate (Xyrem)

Notes:

- Quantity limits: Yes
- * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

<u>Initiation (new start) criteria</u>: Non-formulary **sodium oxybate (Xyrem)** will be covered on the prescription drug benefit for <u>12 months</u> when the following criteria are met:

- 1. Prescribed for the treatment of excessive daytime sleepiness in narcolepsy OR hypersomnia (idiopathic)
 - Prescribed by a Sleep Specialist
 - Patient has failed a trial of, or patient has an allergy or intolerance* to:
 - Modafinil or armodafinil AND
 - A stimulant medication (ie methylphenidate, dextroamphetamine, amphetamine salt combination, etc.) AND
 - Solriamfetol (Sunosi), unless reason for contraindication is provided AND
 - o Pitolisant (Wakix), unless reason for contraindication is provided

-OR-

- 2. Prescribed for the treatment of cataplexy in narcolepsy
 - Prescribed by a Sleep Specialist
 - Patient has failed a trial of, or patient has an allergy or intolerance* to:
 - A tricyclic antidepressant OR
 - A selective serotonin reuptake inhibitor (SSRI) OR
 - A serotonin-norepinephrine reuptake inhibitor (SNRI)

<u>Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously</u>: Non-formulary sodium oxybate (Xyrem) will be covered on the prescription drug benefit for <u>24 months</u> when the following criteria are met:

Prescribed by a Sleep Specialist

kp.org

Revised: 10/14/21 Effective: 12/02/21 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest



Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

Sodium oxybate (Xyrem)

<u>Criteria for new members entering Kaiser Permanente already taking the</u> <u>medication who have not been reviewed previously</u>: Non-formulary sodium oxybate (Xyrem) will be covered on the prescription drug benefit for <u>24 months</u> when the following criteria are met:

• Patient is currently stable on the medication

<u>Continued use criteria for patients stable on the medication</u>: Non-formulary <u>sodium</u> <u>oxybate (Xyrem)</u> will continue to be covered on the prescription drug benefit for <u>24</u> <u>months</u> when the following criteria are met:

Continues to be prescribed by a Sleep Specialist

kp.org

Revised: 10/14/21 Effective: 12/02/21



All plans offered and underwritten by

